Vascular benefits of angiotensin receptor blockers
- PMID: 17594184
- DOI: 10.1517/13543784.16.7.987
Vascular benefits of angiotensin receptor blockers
Abstract
There is convincing evidence that angiotensin II, through activation of the angiotensin II type 1 (AT1) receptor, is involved in the atherosclerotic process. Similarly, angiotensin receptor blockers decrease vascular inflammation, hypertrophy and thrombosis, which are the key components of the progression of atherosclerosis. In addition, in several animal models, angiotensin receptor blockade was able to inhibit atherosclerosis. However, the effects of angiotensin receptor blockers on clinical outcome in cardiovascular patients remains to be established. Contradictory results have been found on the reduction of the risk on myocardial infarctions and in-stent restenosis, although there is solid evidence for cerebroprotective effects of these receptor blockers. These differences may be related to the role of the AT2 receptor. This review discusses the role of angiotensin II and angiotensin receptor blockers in the atherosclerotic process and its translation into clinical practice.
Similar articles
-
The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004. Drugs Aging. 2006. PMID: 16536636 Review.
-
Angiotensin receptor blocker selectivity at the AT1- and AT2-receptors: conceptual and clinical effects.J Renin Angiotensin Aldosterone Syst. 2000 Jun;1(2 Suppl):S6-9. doi: 10.3317/jraas.2000.057. J Renin Angiotensin Aldosterone Syst. 2000. PMID: 17199211 Review.
-
Angiotensin receptor blockers in hypertension and cardiovascular diseases.Cardiovasc Hematol Agents Med Chem. 2006 Jan;4(1):67-73. doi: 10.2174/187152506775268839. Cardiovasc Hematol Agents Med Chem. 2006. PMID: 16529551 Review.
-
Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure.Curr Med Res Opin. 2007 Jul;23(7):1693-705. doi: 10.1185/030079907x210723. Curr Med Res Opin. 2007. PMID: 17588300 Review.
-
Clinical experience with the use of angiotensin receptor blockers in patients with cardiovascular, cerebrovascular and renal diseases.Curr Clin Pharmacol. 2006 May;1(2):139-46. doi: 10.2174/157488406776872532. Curr Clin Pharmacol. 2006. PMID: 18666366 Review.
Cited by
-
Beta-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction.Br J Pharmacol. 2008 Mar;153 Suppl 1(Suppl 1):S298-309. doi: 10.1038/sj.bjp.0707508. Epub 2007 Nov 26. Br J Pharmacol. 2008. PMID: 18037927 Free PMC article. Review.
-
Effects of angiotensin receptor blockers on neointimal characteristics in angina patients requiring stent implantation: optical coherence tomography analysis.BMC Cardiovasc Disord. 2017 Nov 15;17(1):278. doi: 10.1186/s12872-017-0709-9. BMC Cardiovasc Disord. 2017. PMID: 29141596 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
